A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the efficacy and safety of nebivolol monotherapy in Hispanic patients with stage 1 or stage 2 hypertension

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Forest Laboratories
• Treatments: Nebivolol

Criteria

Inclusion Criteria:

• Male and female outpatients 18 to 80 years of age, self-identified as Hispanic or Latino ethnicity

• Females must be post-menopausal, or not pregnant and using an approved contraceptive regimen

• Meet criteria for stage I or II hypertension

• Currently not treated, or being treated with no more than two anti-hypertensive medications

Exclusion Criteria:

• Secondary hypertension

• Are taking three or more antihypertensive agents

• Have uncontrolled or poorly controlled diabetes mellitus type I or type II

• Evidence of other concurrent disease or conditions that might interfere with the conduct of the study

• Participation in any investigational study within 30 days of Screening (Visit 1).

• Have a history of hypersensitivity to nebivolol or other β-blockers, or any contraindication to β-blocker use